Mga Batayang Estadistika
| CIK | 1510580 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kite Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| October 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36508 Kite Pharma, Inc. (Exact name of registrant as specified in its ch |
|
| October 5, 2017 |
KITE / Kite Pharma, Inc. / JP Morgan Chase & Co - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* KITE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49803L109 (CUSIP Number) September 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| October 3, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on October 3, 2017 Registration No. |
|
| October 3, 2017 |
S-8 POS 1 d468640ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 3, 2017 Registration No. 333-196978 Registration No. 333-203014 Registration No. 333-209809 Registration No. 333-216296 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-196978 POST-EFFECTIVE AMENDMENT NO |
|
| October 3, 2017 |
Form S-8 POS As filed with the Securities and Exchange Commission on October 3, 2017 Registration No. |
|
| October 3, 2017 |
Form S-8 POS As filed with the Securities and Exchange Commission on October 3, 2017 Registration No. |
|
| October 3, 2017 |
POSASR As filed with the Securities and Exchange Commission on October 3, 2017 Registration No. |
|
| October 3, 2017 |
8-K 1 d458818d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2017 Kite Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36508 27-1524986 (State or Other Jurisdiction of Incorp |
|
| October 3, 2017 |
Amended and Restated Bylaws of the Company. EX-3.2 Exhibit 3.2 BY-LAWS OF KITE PHARMA, INC. A Delaware Corporation Effective October 3, 2017 TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings 1 Section 2. Annual Meetings 1 Section 3. Special Meetings 2 Section 4. Notice 2 Section 5. Adjournments 3 Section 6. Quorum 3 Section 7. V |
|
| October 3, 2017 |
Amended and Restated Certificate of Incorporation of the Company. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KITE PHARMA, INC. FIRST: The name of the Corporation is Kite Pharma, Inc. (hereinafter the ?Corporation?). SECOND: The address of the registered office of the Corporation in the State of Delaware is the Corporation Trust Company, 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at t |
|
| October 3, 2017 |
SC 14D9/A 1 d377299dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE ( |
|
| October 3, 2017 |
GILEAD SCIENCES COMPLETES TENDER OFFER FOR ALL OUTSTANDING SHARES OF KITE PHARMA, INC. Exhibit (a)(5)(P) CONTACTS: Sung Lee, Investors (650) 524-7792 Amy Flood, Media (650) 522-5643 Confidential - DRAFT GILEAD SCIENCES COMPLETES TENDER OFFER FOR ALL OUTSTANDING SHARES OF KITE PHARMA, INC. |
|
| October 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per S |
|
| September 26, 2017 |
SC 14D9/A 1 d420556dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE ( |
|
| September 26, 2017 |
Joint Press Release issued by Kite Pharma, Inc. and Gilead Sciences, Inc., dated September 26, 2017. Exhibit (a)(5)(O) Exhibit (a)(5)(O) CONTACTS Gilead Sung Lee, Investors (650) 524-7792 Amy Flood, Media (650) 522-5643 Kite Christine Cassiano, Investors & Media (424) 532-5084 For Immediate Release GILEAD SCIENCES AND KITE PHARMA ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD Foster City, Calif. |
|
| September 26, 2017 |
GILEAD SCIENCES AND KITE PHARMA ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD Exhibit (a)(5)(O) CONTACTS Gilead Kite Sung Lee, Investors Christine Cassiano, Investors & Media (650) 524-7792 (424) 532-5084 Amy Flood, Media (650) 522-5643 For Immediate Release GILEAD SCIENCES AND KITE PHARMA ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD Foster City, Calif. |
|
| September 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per S |
|
| September 25, 2017 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49 |
|
| September 25, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2017 Kite Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36508 27-1524986 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per S |
|
| September 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per S |
|
| September 18, 2017 |
Project Dodgers Joinder Agreement EX-99.(B)(2) 3 a17-222251ex99db2.htm EX-99.(B)(2) Exhibit (b)(2) PERSONAL AND CONFIDENTIAL September 8, 2017 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Attention: Peter C. Hall Bank of America, N.A. One Bryant Park New York, New York 10036 Attention: Joseph Corah Wells Fargo Securities, LLC 550 S. Tryon Street Charlotte, North Carolina 28202 Attenti |
|
| September 18, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per S |
|
| September 18, 2017 |
Exhibit (b)(1) Execution Version BANK OF AMERICA, N.A. MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED One Bryant Park New York, New York 10036 WELLS FARGO BANK, NATIONAL ASSOCIATION WELLS FARGO SECURITIES, LLC 550 S. Tryon Street Charlotte, North Carolina 28202 CONFIDENTIAL August 31, 2017 GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City, CA 94404 Attention: Robin L. Washington, Executive |
|
| September 15, 2017 |
Cover Email to Kite Pharma, Inc. employees, first used on September 15, 2017. EX-99.(a)(5)(N) Exhibit (a)(5)(N) Please find attached the latest Q&A update from the Integration Team. Please note that for administrative reasons in connection with the transaction, we are closing the trading window a few days early. The window will now close after-market on September 26, 2017. As always, if you have any questions, please don?t hesitate to send them to me. Thanks ? Christine Chr |
|
| September 15, 2017 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49 |
|
| September 15, 2017 |
Additional Q&A provided to Kite Pharma, Inc. employees, first used on September 15, 2017. EX-99.(a)(5)(M) Exhibit (a)(5)(M) Q&A 9/15/17 KEY GENERAL QUESTIONS Q1: Are there any updates as to when the acquisition will be complete? We are on track to meet our target close date in early October 2017, subject to the terms and conditions of the merger agreement and Gilead?s offer to purchase, as announced. Q2: How does this transaction affect my current role and future work? We remain focuse |
|
| September 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per S |
|
| September 8, 2017 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49 |
|
| September 7, 2017 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49 |
|
| September 7, 2017 |
EX-(a)(5)(L) Exhibit a(5)(L) September 6, 2017 Information Regarding the Kite Employee Stock Purchase Plan We have received many questions about the Employee Stock Purchase Plan (the ?ESPP?) as it relates to Gilead?s acquisition of Kite and want to share some important information regarding your participation in the plan. |
|
| September 5, 2017 |
Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica, California 90404 EX-(a)(5)(K) EXHIBIT (a)(5)(K) Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica, California 90404 September 5, 2017 To Our Stockholders: As we previously announced, on August 27, 2017, Kite Pharma, Inc. (?Kite?) entered into a merger agreement providing for the acquisition of Kite by Gilead Sciences, Inc. (?Gilead?). In the acquisition, Kite stockholders will receive $180.00 for each share of K |
|
| September 5, 2017 |
MUTUAL CONFIDENTIALITY AGREEMENT EX-(e)(2) Exhibit (e)(2) Confidential MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (?Agreement?) is effective as of February 10, 2017 (?Effective Date?), between Kite Pharma, Inc. |
|
| September 5, 2017 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 5, 2017 |
GILEAD SCIENCES, INC. AMENDMENT NO. 1 TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT EX-(e)(3) Exhibit (e)(3) GILEAD SCIENCES, INC. AMENDMENT NO. 1 TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Amendment No. 1 (this ?Amendment?) to the Mutual Confidential Disclosure Agreement dated February 10, 2017 (the ?Original Agreement?) is made effective as of August 20, 2017 (?Amendment Effective Date?) by and between Gilead Sciences, Inc. (?Company?) and Kite Pharma, Inc. (?Kite?). Capi |
|
| September 5, 2017 |
Form of Excise Tax Reimbursement Payment Letter Agreement. EX-10.1 2 d452149dex101.htm EX-10.1 Exhibit 10.1 [Kite Letterhead] [Date] [Name] [Address] [Address] Dear [Name]: This letter agreement (this “Agreement”) confirms the understanding between you and Kite Pharma, Inc. (the “Company”) regarding certain payment, reimbursement treatment that you may become entitled to receive in connection with the acquisition (the “Acquisition”) of the Company by Gile |
|
| September 5, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2017 Kite Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36508 27-1524986 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 5, 2017 |
SC TO-T 1 a2233171zscto-t.htm SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD S |
|
| September 5, 2017 |
EX-99.1(A)(1)(C) 4 a2233171zex-991a1c.htm EX-99.1(A)(1)(C) QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of KITE PHARMA, INC. a Delaware corporation at $180.00 NET PER SHARE Pursuant to the Offer to Purchase dated September 5, 2017 by DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD |
|
| September 5, 2017 |
EX-99.1(A)(1)(F) 7 a2233171zex-991a1f.htm EX-99.1(A)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated September 5, 2017, and the related Letter of Transmittal, and any amendments or supplements to such Offer to Purchase or L |
|
| September 5, 2017 |
EX-99.1(A)(1)(D) 5 a2233171zex-991a1d.htm EX-99.1(A)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of KITE PHARMA, INC. a Delaware corporation at $180.00 NET PER SHARE Pursuant to the Offer to Purchase dated September 5, 2017 by DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE |
|
| September 5, 2017 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of KITE PHARMA, INC. |
|
| September 5, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of KITE PHARMA, INC. |
|
| September 5, 2017 |
EX-99.1(A)(1)(B) 3 a2233171zex-991a1b.htm EX-99.1(A)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of KITE PHARMA, INC. a Delaware corporation at $180.00 NET PER SHARE Pursuant to the Offer to Purchase Dated September 5, 2017 by DODGERS MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTE |
|
| September 1, 2017 |
EX-99.1 Exhibit 99.1 Gilead and Kite Agreement Q: What was announced on August 28, 2017? Gilead announced an agreement to acquire Kite Pharma for $180 per share, or approximately $11.9 billion. The acquisition will be structured as a tender offer directly to shareholders. Q: What is a ?tender offer?? A tender offer is a broad solicitation by a company (in this case Gilead) to purchase a substantia |
|
| September 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49803L109 (CUSIP Number of Cla |
|
| September 1, 2017 |
EX-99.2 Exhibit 99.2 Dear Team, Thank you for your attendance and your thoughtful questions at the all-staff meeting on Monday. Please find attached the latest Kite-Gilead Q&A document to clarify the treatment of equity and payment of 2017 bonuses, which is expected to be paid in the ordinary course following year end. To summarize, unvested options and unvested RSUs will convert to Gilead options |
|
| September 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 49803L109 (Cusip Number of Class |
|
| September 1, 2017 |
Exhibit 99.2 Dear Team, Thank you for your attendance and your thoughtful questions at the all-staff meeting on Monday. Please find attached the latest Kite-Gilead Q&A document to clarify the treatment of equity and payment of 2017 bonuses, which is expected to be paid in the ordinary course following year end. To summarize, unvested options and unvested RSUs will convert to Gilead options and RSU |
|
| September 1, 2017 |
Exhibit 99.1 Gilead and Kite Agreement Q: What was announced on August 28, 2017? Gilead announced an agreement to acquire Kite Pharma for $180 per share, or approximately $11.9 billion. The acquisition will be structured as a tender offer directly to shareholders. Q: What is a ?tender offer?? A tender offer is a broad solicitation by a company (in this case Gilead) to purchase a substantial percen |
|
| August 30, 2017 |
CORRESP 1 filename1.htm August 30, 2017 VIA FEDEX AND EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attention: Suzanne Hayes RE: Kite Pharma, Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed February 28, 2017 File No. 001-36508 Dear Ms. Hayes: We are writing in response to comments rec |
|
| August 28, 2017 |
ALL-STAFF INTERNAL ANNOUNCEMENT EX-99.6 7 d448326dex996.htm EX-99.6 Exhibit 99.6 ALL-STAFF INTERNAL ANNOUNCEMENT August 28, 2017 Dear Kite Team: Kite is making history yet again. Today we announced that Gilead will acquire Kite for $11.9 billion dollars, or $180 per share. A copy of today’s press release can be found on our website. This is exciting news for all of us at Kite and is a testament to the strong business we have bui |
|
| August 28, 2017 |
KEY INVESTOR QUESTIONS INVESTOR RELATIONS EX-99.3 Exhibit 99.3 KEY INVESTOR QUESTIONS INVESTOR RELATIONS 1. What role will your executive team have after the Merger? Will Arie, David, Shawn and Tim stay on? Gilead views our team as a key strength. We will provide more details on these matters as we proceed toward closing. 2. What is the status of the FDA review? Is it still on track? Yes. The review process is moving forward. On our Secon |
|
| August 28, 2017 |
EX-99.1 Exhibit 99.1 Kite Internal Messaging Kite is making history yet again. We are excited to announce that Gilead will acquire Kite for $11.9 billion dollars, or $180 per share. This great news for all of us at Kite and is a testament to the strong business we have built as a pioneer and leader in cell therapy. All of this is clearly a reflection of the talent and accomplishments that are |
|
| August 28, 2017 |
EX-99.4 5 d448326dex994.htm EX-99.4 Exhibit 99.4 Gilead and Kite Agreement Q: What was announced on August 28, 2017? Gilead announced an agreement to acquire Kite Pharma for $180 per share, or approximately $11.9 billion. The acquisition will be structured as a tender offer directly to shareholders. Q: What is a “tender offer”? A tender offer is a broad solicitation by a company (in this case Gile |
|
| August 28, 2017 |
EX-99.2 Exhibit 99.2 KEY INTERNAL KITE QUESTIONS GENERAL TRANSACTION INFORMATION 1. What does Gilead do? Gilead is a science-focused biopharmaceutical company with a clear mission: improving care for people with life-threatening diseases around the world. The company developed the world?s first once-daily, single tablet regimen for HIV, ushering in a new era in treatment. More recently, the compan |
|
| August 28, 2017 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. (Name of Subject Company) Kite Pharma, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49803L109 (CUSIP Numbe |
|
| August 28, 2017 |
EX-99.5 Exhibit 99.5 RESPONSE TO INVESTOR INQUIRY Dear [ ], Thank you for contacting Kite. On August 28, 2017, Kite announced it has entered an agreement with Gilead Sciences, Inc. to be acquired for $11.9 billion or $180 per share in cash. We expect the transaction to close in the fourth quarter of 2017. Until then, Kite will continue to operate as an independent company and we will continue our |
|
| August 28, 2017 |
Exhibit 99.3 Severin, Chade (BOS) From: Sent: To: Subject: Attachments: Employee Communications Monday, August 28, 2017 9:41 AM #Operating Group; #Senior Directors Message from John Milligan: Kite Acquisition GILD Infographic.pdf; 08.28.17 Gilead Kite Press Release.pdf To Operating Group and Senior Directors, As you have seen from the attached press release, this morning we announced an agreement |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 Exhibit 99.6 Gilead Tweets (@Gilead), August 28, 2017 Kite provides foundation from which to drive continued innovation for people w/ advanced cancers?- GILD CEO John Milligan https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 EX-99.11 12 a17-210671ex99d11.htm EX-99.11 Exhibit 99.11 Gilead Tweets (@Gilead), August 28, 2017 Learn more about our acquisition of @KitePharma https://t.co/xOK5wUSlcB https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 EX-99.5 6 a17-210671ex99d5.htm EX-99.5 Exhibit 99.5 Gilead Tweets (@Gilead), August 28, 2017 BREAKING: Gilead to acquire @KitePharma, industry leader in emerging field of cell therapy, for $11.9 B in cash https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 EX-99.7 8 a17-210671ex99d7.htm EX-99.7 Exhibit 99.7 Gilead Tweets (@Gilead), August 28, 2017 Addition of @KitePharma immediately positions Gilead as a leader in cell therapy for hematological cancers https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 Exhibit 99.9 Gilead Tweets (@Gilead), August 28, 2017 Acquisition of @KitePharma leverages Gilead expertise in rapidly advancing therapies to address unmet patient needs https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
Gilead to Acquire Kite: Creating a Global Leader in Cell Therapy August 28, 2017 Exhibit 99.1 Gilead to Acquire Kite: Creating a Global Leader in Cell Therapy August 28, 2017 Disclaimer and Forward-Looking Statements This presentation includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements th |
|
| August 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KITE PHARMA, INC. (Name of Subject Company (Issuer)) DODGERS MERGER SUB, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 49803L109 (Cusip Number of Class |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 Exhibit 99.10 Gilead Tweets (@Gilead), August 28, 2017 Gilead management to host investor conference call today at 8 AM ET / 5 AM PT www.gilead.com/investors https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
EX-99.2 3 a17-210671ex99d2.htm EX-99.2 Exhibit 99.2 Advances Gilead’s Mission to Bring Life-Saving Products to as Many People as Possible TRANSACTION HIGHLIGHTS review in the EU ~$11.9 B Transaction value $180.00 per share in cash axi-cel utilization in earlier lines of therapy in FINANCIAL BENEFITS > Will add shareholder value and provide opportunities for diversification of revenues > Expected t |
|
| August 28, 2017 |
Gilead Tweets (@Gilead), August 28, 2017 EX-99.8 9 a17-210671ex99d8.htm EX-99.8 Exhibit 99.8 Gilead Tweets (@Gilead), August 28, 2017 Kite has leading investigational product in a disease w/ unmet medical need; approval process underway in U.S. and EU https://t.co/KAtiQS2rlT |
|
| August 28, 2017 |
Exhibit 99.4 Severin, Chade (BOS) From: Sent: To: Subject: Amy Flood Monday, August 28, 2017 7:10 AM Marni Kottle; Nathan Kaiser FW: On Behalf of John Milligan, CEO of Gilead This has been sent From: Christine Cassiano [mailto:[email protected]] Sent: Monday, August 28, 2017 4:09 AM To: DL-Kite Pharma US employees; DL-Kite Pharma EU employees Subject: On Behalf of John Milligan, CEO of Gile |
|
| August 28, 2017 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: KITE PHARMA, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and DODGERS MERGER SUB, INC., a Delaware corporation Dated as of August 27, 2017 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 4 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the Company 6 2.2 Effe |
|
| August 28, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2017 Kite Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36508 27-1524986 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 28, 2017 |
EX-99.1 Exhibit 99.1 CONTACTS Gilead Sung Lee, Investors (650) 524-7792 Amy Flood, Media (650) 522-5643 Kite Christine Cassiano, Investors & Media (424) 532-5084 For Immediate Release GILEAD SCIENCES TO ACQUIRE KITE PHARMA FOR $11.9 BILLION ? Immediately Positions Gilead as a Leader in Cell Therapy ? ? Kite?s Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. |
|
| August 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 8, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 8, 2017 |
Kite Reports Second Quarter 2017 Financial Results EX-99.1 Exhibit 99.1 Kite Reports Second Quarter 2017 Financial Results Filed Industrys First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel for Potential EU Approval and Launch in 2018 Submitted Investigational New Drug Application for KITE-585, a CAR-T Candidate that Targets BCMA in Multiple Myeloma Conference Call Today at 5:30 AM PDT / 8:30 AM EDT SANTA |
|
| August 8, 2017 |
KITE / Kite Pharma, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36508 KITE PHARM |
|
| June 23, 2017 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commissio |
|
| May 8, 2017 |
Kite Pharma 10-Q FY2017 Q1 (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36508 |
|
| May 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 8, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 8, 2017 |
Kite Reports First Quarter Financial Results EX-99.1 Exhibit 99.1 Kite Reports First Quarter Financial Results Completed Submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Kites CAR-T Therapy, Axicabtagene Ciloleucel, in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) Initiated Two New Clinical Studies as Part of an Expanded KTE-C19 Development Program Advanced Additional New Cell |
|
| May 8, 2017 |
COLLABORATION AND LICENSE AGREEMENT EX-10.1 2 a101.htm EXHIBIT 10.1 Exhibit 10.1 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. EXECUTION VERSION CONFIDENTIAL COLLABORATION AND LICENSE AGREEMENT by and between Kite Pharma EU B.V. And Daiichi Sankyo Company, Lim |
|
| May 8, 2017 |
Exhibit 10.2 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. Execution Version Sino-foreign Co-operative Joint Venture Contract by and between KP EU C.V. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. regar |
|
| April 28, 2017 |
DEFA14A 1 d346531ddefa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement |
|
| April 28, 2017 |
Kite Pharma DEFINITIVE PROXY STATEMENT Definitive Proxy Statement SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 10, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 16, 2017 |
EX-99.1 Exhibit 99.1 Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors SANTA MONICA, Calif., March 16, 2017 ? Kite Pharma, Inc. (Nasdaq:KITE) today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles (UCLA) and a |
|
| March 16, 2017 |
8-K 1 d535018d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 14, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of inco |
|
| March 6, 2017 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-208382 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.001 per share 5,462,500 $75.00 $409,687,500 $47,483 (1) Includes |
|
| March 6, 2017 |
4,750,000 Shares of Common Stock Kite Pharma, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 EXECUTION VERSION 4,750,000 Shares of Common Stock Kite Pharma, Inc. UNDERWRITING AGREEMENT March 2, 2017 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Kite Pharma, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several underwriters nam |
|
| March 6, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 2, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 2, 2017 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-208382 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| February 28, 2017 |
S-8 1 d350922ds8.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KITE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 27-1524986 (State or other jurisdiction of incorporation or |
|
| February 28, 2017 |
Kite Reports Fourth Quarter and Full Year 2016 Financial Results EX-99.1 Exhibit 99.1 Kite Reports Fourth Quarter and Full Year 2016 Financial Results ? Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 ? On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 ? Potential U.S. Approval and Launch of Axica |
|
| February 28, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 28, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commis |
|
| February 28, 2017 |
Kite Pharma 10-K (Annual Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36508 KITE PHARMA, INC. |
|
| February 28, 2017 |
KITE PHARMA, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) Exhibit 10.3 KITE PHARMA, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) Kite Pharma, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby grants to Participant an option to purchase the number of shares of the Common Stock set forth below (the “Option”). This Option is subject to all of the terms and conditions as set forth in this notice, in the Stoc |
|
| February 28, 2017 |
KITE PHARMA, INC. (2014 EQUITY INCENTIVE PLAN) NOTICE OF GRANT Exhibit 10.4 KITE PHARMA, INC. (2014 EQUITY INCENTIVE PLAN) NOTICE OF GRANT Kite Pharma, Inc. (the “Company”), pursuant to Section 11 of the Company’s 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and condi |
|
| February 28, 2017 |
Exhibit 10.5 KITE PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: JUNE 6, 2014 AMENDED: DECEMBER 17, 2015, DECEMBER 12, 2016 AND JANUARY 3, 2017 Each member of the Board of Directors (the “Board”) of Kite Pharma, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employ |
|
| February 28, 2017 |
EX-21.1 5 kite20161231ex211.htm EXHIBIT 21.1 Exhibit 21.1 Kite Pharma, Inc. The following is a list of subsidiaries of Kite Pharma, Inc. as of December 31, 2016: Name Jurisdiction of Incorporation Kite Pharma, LLC Delaware Kite Pharma UK, Ltd. United Kingdom KP EU C.V. The Netherlands Kite Pharma EU B.V. The Netherlands |
|
| February 15, 2017 |
KITE / Kite Pharma, Inc. / Belldegrun Arie - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) KITE PHARMA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49803L 10 9 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 10, 2017 |
Kite Pharma 3G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 kitepharmainc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Kite Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 49803L109 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designate the rule pursuant to which |
|
| January 10, 2017 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2017 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commiss |
|
| January 5, 2017 |
Kite Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 3, 2017 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commissi |
|
| January 5, 2017 |
EX-99.1 2 d245373dex991.htm EX-99.1 Exhibit 99.1 Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors SANTA MONICA, Calif., Jan. 5, 2017 — Kite Pharma, Inc. (Nasdaq:KITE) today announced that Ian T. Clark, former Chief Executive Officer, Head of Commercial Operations and member of the Board of Directors for Genentech Inc., a member of the Roche G |
|
| December 27, 2016 |
8-K 1 d273976d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 22, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of i |
|
| November 9, 2016 |
Kite Pharma Reports Third Quarter 2016 Financial Results EX-99.1 Exhibit 99.1 Kite Pharma Reports Third Quarter 2016 Financial Results ? Company Announces Plans to Initiate a Rolling Submission of the Biologics License Application for KTE-C19 with the U.S. Food and Drug Administration for an Expanded Indication of Aggressive Non-Hodgkin Lymphoma in December 2016 with a Targeted Completion in Q1 2017 ? Potential Approval and Commercial Launch of KTE-C19 |
|
| November 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 9, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2016 |
Kite Pharma 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36 |
|
| November 9, 2016 |
EX-10.1 2 kiteex-1019x30x16.htm EXHIBIT 10.1 Exhibit 10.1 COLORADO CENTER OFFICE LEASE This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between CA-COLORADO CENTER, L.L.C., a Delaware limited liability company ("Landlord"), and KITE PHARMA, INC., a Delaware corporation ("Tenant"). SUMMARY OF |
|
| September 26, 2016 |
Exhibit 99.1 Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) Study Met Primary Endpoint of Objective Response Rate (p<0.0001) at Interim Analysis First Multicenter Pivotal Trial of CAR-T Therapy to Report Positive Outcome Company Plans to Present Additional Data at Upcoming Scientific Meeting SANTA MONICA, Calif. |
|
| September 26, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 d265635d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 26, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of |
|
| August 8, 2016 |
EX-99.1 Exhibit 99.1 Kite Pharma Reports Second Quarter 2016 Financial Results Interim Results from Pivotal Phase 2 Portion of ZUMA-1 Clinical Trial of KTE-C19 Expected in Late Third Quarter of 2016 KTE-C19 Biologics License Application Filing Planned in Late 2016; Commercial Launch of KTE-C19 Expected in 2017 Kite Investor Day Scheduled for October 18, 2016 Conference Call to Be Held Today at 4:3 |
|
| August 8, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 8, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2016 |
Kite Pharma 10-Q (Quarterly Report) kite-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| August 8, 2016 |
EX-10.1 2 kite-ex101427.htm EX-10.1 Exhibit 10.1 May 3, 2016 Mr. Paul Jenkinson 33671 Paseo Del Puerto San Juan Capistrano, CA 92675 Re: Employment Letter Dear Mr. Jenkinson: Kite Pharma, Inc. (“Kite” or the “Company”) is pleased to offer you the position of Chief Financial Officer, on the following terms and conditions: 1. Title; Reporting; Duties. (a) As Chief Financial Officer, you will perform |
|
| August 8, 2016 |
EX-10.2 3 kite-ex102428.htm EX-10.2 Exhibit 10.2 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between AMGEN INC. and KITE PHARMA, INC. Dated as of December 31, 2014 Amgen |
|
| August 8, 2016 |
RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.3 4 kite-ex103429.htm EX-10.3 Exhibit 10.3 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. CONFIDENTIAL EXECUTION VERSION RESEARCH COLLABORATION AND LICENSE AGREEMENT This RESEARCH COLLABORATION AND LICENSE AGREEMENT (th |
|
| July 22, 2016 |
Response Letter July 22, 2016 Via FedEx and EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 6, 2016 |
AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET EX-10.1 Exhibit 10.1 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?), dated for reference puposes only as of July 1, 2016, is made by and between 2383 UTAH, LLC, a Delaware limited liability company (?Lessor?) and KITE PHARMA, INC., a Delaware corporation (?Lessee?), (collecti |
|
| July 6, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 1, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2016 |
Kite Pharma FORM 10-Q/A (Quarterly Report) 10-Q/A 1 d391702d10qa.htm FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (AMENDMENT NO. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per |
|
| June 28, 2016 |
Kite Pharma FORM 10-K/A (Annual Report) FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (AMENDMENT NO. |
|
| June 28, 2016 |
CORRESP June 28, 2016 VIA FEDEX AND EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 6, 2016 |
Kite Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission |
|
| June 2, 2016 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2016 |
Exhibit 99.1 Kite Pharma Expands Leadership Team, Appoints Paul L. Jenkinson as Chief Financial Officer Led Worldwide Commercial and Corporate Financial Planning Functions at Allergan SANTA MONICA, Calif., May 16, 2016 Kite Pharma, Inc. (Nasdaq: KITE) today announced the appointment of Paul L. Jenkinson as Chief Financial Officer, reporting to Arie Belldegrun, M.D., FACS, Kites Chairman, Presid |
|
| May 16, 2016 |
8-K 1 d168986d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 16, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorp |
|
| May 9, 2016 |
EX-99.1 Exhibit 99.1 Kite Pharma Reports First Quarter 2016 Financial Results Durable Treatment Effect of KTE-C19 Supported by Updated Patient Follow-up in ZUMA-1 Trial Presented at Annual Meeting of the American Association of Cancer Research (AACR) Interim Results from Pivotal Phase 2 Portion of KTE-C19 ZUMA-1 Trial Expected in Second Half of 2016, to Support Planned BLA Filing in Late 2016 and |
|
| May 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 9, 2016 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 9, 2016 |
Kite Pharma 10-Q (Quarterly Report) 10-Q 1 kite-10q20160331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 9, 2016 |
National Institutes of Health SECOND AMENDMENT TO L-068-2013/0 EX-10.2 3 kite-ex102283.htm EX-10.2 Exhibit 10.2 National Institutes of Health SECOND AMENDMENT TO L-068-2013/0 This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of April 11, 2013 and having NIH Reference Number L-068-2 |
|
| May 9, 2016 |
National Institutes of Health SECOND AMENDMENT TO L-077-2015/0 EX-10.4 5 kite-ex104285.htm EX-10.4 Exhibit 10.4 National Institutes of Health SECOND AMENDMENT TO L-077-2015/0 This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of December 31, 2014 and having NIH Reference Number L-07 |
|
| May 9, 2016 |
National Institutes of Health FIRST AMENDMENT TO L-002-2016/0 EX-10.5 6 kite-ex105286.htm EX-10.5 Exhibit 10.5 National Institutes of Health FIRST AMENDMENT TO L-002-2016/0 This is the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of October 1, 2015 and having NIH Reference Number L-002-201 |
|
| May 9, 2016 |
National Institutes of Health SECOND AMENDMENT TO L-277-2014/0 Exhibit 10.3 National Institutes of Health SECOND AMENDMENT TO L-277-2014/0 This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of June 2, 2014 and having NIH Reference Number L-277-2014/0 (“Agreement”). This Second Amend |
|
| May 9, 2016 |
Exhibit 10.1 February 9, 2016 Mr. Timothy Moore 608B Missouri St. San Francisco, CA 94107 Re: Employment Letter Dear Mr. Moore: Kite Pharma, Inc. (“Kite” or the “Company”) is pleased to offer you the position of Executive Vice President, Technical Operations, on the following terms and conditions: 1. Title; Reporting; Duties. (a) As Executive Vice President, Technical Operations, you will perform |
|
| April 21, 2016 |
DEF 14A 1 d180188ddef14a.htm DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ |
|
| April 21, 2016 |
DEFA14A 1 d171941ddefa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement |
|
| February 29, 2016 |
S-8 1 d145887ds8.htm S-8 As filed with the Securities and Exchange Commission on February 29, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KITE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 27-1524986 (State or other jurisdiction of incorporation or |
|
| February 29, 2016 |
EX-99.1 EXHIBIT 99.1 Kite Pharma Reports Fourth Quarter and Full-Year 2015 Financial Results - Interim KTE-C19 Data, Expected in Second Half of 2016, to Support Planned BLA Filing in Late 2016 and Potential Product Launch in 2017 - - Balance Sheet Further Strengthened Through 2015 Public Offering, $614.7 Million in Cash and Investments - SANTA MONICA, Calif., Feb. 29, 2016 ? Kite Pharma, Inc. (Nas |
|
| February 29, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 29, 2016 KITE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File |
|
| February 29, 2016 |
Kite Pharma 10-K (Annual Report) kite-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| February 29, 2016 |
License and research AGREEMENT EX-10.30 8 kite-ex1030304.htm EX-10.30 Signature Version Exhibit 10.30 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. License and research AGREEMENT This License and Research Agreement (the “Agreement”) is effective as of Oc |
|
| February 29, 2016 |
THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT – EXCLUSIVE COVER PAGE EX-10.29 7 kite-ex1029303.htm EX-10.29 Exhibit 10.29 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT – EXCLUSIVE COVER PAGE For NIH internal use only: License Number: |
|
| February 29, 2016 |
EX-10.3 2 kite-ex103749.htm EX-10.3 Exhibit 10.3 KITE PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: JUNE 6, 2014 AMENDED: DECEMBER 17, 2015 Each member of the Board of Directors (the “Board”) of Kite Pharma, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee |
|
| February 29, 2016 |
National Institutes of Health FIRST AMENDMENT TO L-277-2014/0 Exhibit 10.23 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. National Institutes of Health FIRST AMENDMENT TO L-277-2014/0 This is the first amendment (“First Amendment”) of the agreement by and between the National Institute |
|
| February 29, 2016 |
EX-10.5 3 kite-ex105299.htm EX-10.5 Exhibit 10.5 Kite Pharma, Inc. Change in Control and Severance Benefit Plan Approved by the Board of Directors: December 17, 2015 Section 1. Introduction. The Kite Pharma, Inc. Severance and Change in Control Benefit Plan (the “Plan”) is hereby established effective December 17, 2015 (the “Effective Date”). The purpose of the Plan is to provide for the payment o |
|
| February 29, 2016 |
National Institutes of Health FIRST AMENDMENT TO L-068-2013/0 EX-10.21 5 kite-ex1021301.htm EX-10.21 Exhibit 10.21 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. National Institutes of Health FIRST AMENDMENT TO L-068-2013/0 This is the first amendment (“First Amendment”) of the agreeme |
|
| February 29, 2016 |
Proprietary Information and Invention Assignment Agreement EX-10.13 4 kite-ex1013300.htm EX-10.13 Exhibit 10.13 December 16, 2015 Ms. Shawn Tomasello 3508 Burnt Pine Lane Miramar Beach, FL 32550-1836 Re:Employment Letter Dear Ms. Tomasello: Kite Pharma, Inc. (“Kite” or the “Company”) is pleased to offer you the position of Chief Commercial Officer, on the following terms and conditions: 1. Title; Reporting; Duties. (a) As Chief Commercial Officer, you wil |
|
| February 12, 2016 |
SC 13G/A 1 schedule13ga.htm KITE PHARMA SCHEDULE 13GA 2-12-16 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kite Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 49803L109 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) |
|
| February 12, 2016 |
Kite Pharma SC 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 d140038dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) KITE PHARMA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49803L 10 9 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 10, 2016 |
Kite Pharma 3G (Passive Acquisition of More Than 5% of Shares) kitepharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Kite Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 49803L109 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate box to des |
|
| December 22, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 17, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission |
|
| December 11, 2015 |
3,625,000 Shares of Common Stock Kite Pharma, Inc. UNDERWRITING AGREEMENT EX-1.1 2 d44927dex11.htm EX-1.1 Exhibit 1.1 3,625,000 Shares of Common Stock Kite Pharma, Inc. UNDERWRITING AGREEMENT December 9, 2015 JEFFERIES LLC CITIGROUP GLOBAL MARKETS INC. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CITIGROUP GLOBAL MARKETS INC. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: Introducto |
|
| December 11, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 9, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission F |
|
| December 11, 2015 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No: 333-208382 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. |
|
| December 8, 2015 |
EX-4.8 5 d45969dex48.htm EX-4.8 Exhibit 4.8 KITE PHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KITE PHARMA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KITE PHARMA, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] org |
|
| December 8, 2015 |
EX-4.4 2 d45969dex44.htm EX-4.4 Exhibit 4.4 KITE PHARMA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and T |
|
| December 8, 2015 |
EX-4.7 Exhibit 4.7 KITE PHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KITE PHARMA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between KITE PHARMA, INC., a Delaware corporation (the ?Company?) and [?], a [corporation] [national banking association] organized and existing under |
|
| December 8, 2015 |
424B5 1 d91671d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No: 333-208382 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prosp |
|
| December 8, 2015 |
EX-99.1 2 d18180dex991.htm EX-99.1 Exhibit 99.1 As used in this Current Report on Form 8-K, all references to “we,” “us,” “our,” “Kite Pharma,” the “Company” and similar designations refer to Kite Pharma, Inc. and its subsidiaries on a consolidated basis. This Current Report on Form 8-K contains common law, unregistered trademarks for Kite Pharma and eACT based on use of the trademarks in the Unit |
|
| December 8, 2015 |
S-3ASR 1 d45969ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on December 8, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1524986 (State or other jurisdic |
|
| December 8, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 8, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File |
|
| December 8, 2015 |
EX-4.6 3 d45969dex46.htm EX-4.6 Exhibit 4.6 KITE PHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KITE PHARMA, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KITE PHARMA, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized an |
|
| December 8, 2015 |
EX-12.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND RATIO OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS (in thousands, except ratios) The following table sets forth our ratio of earnings to fixed charges and our ratio of earnings to combined fixed charges and preferred stock dividends for the years ended December 31, 2014, 2013 and 2 |
|
| December 7, 2015 |
EX-99.1 Exhibit 99.1 Kite Pharma Presents Phase 1 Results from ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) ? Kite Pharma, Inc. (Nasdaq:KITE) today announced clinical results and biomarker data for the phase 1 portion of Kite?s ZUMA-1 trial of KTE-C19 in patients with refractory, aggressive non-Hodgkin lymphoma (NHL). KT |
|
| December 7, 2015 |
Kite Pharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 7, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission F |
|
| November 12, 2015 |
Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update Santa Monica, Calif., November 12, 2015 (GLOBENEWSWIRE) ? Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT?) products for the treatment of cancer, today reported financial results for the quarter ended |
|
| November 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36508 KITE |
|
| November 12, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 12, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File |
|
| November 5, 2015 |
Kite Pharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 5, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission F |
|
| November 5, 2015 |
EX-99.1 2 d54942dex991.htm EX-99.1 Exhibit 99.1 Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH) SANTA MONICA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) — Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced upcoming presentatio |
|
| October 27, 2015 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 26, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commiss |
|
| October 20, 2015 |
EX-99.1 Exhibit 99.1 Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE SANTA MONICA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) ? Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT?) products for the treatment of |
|
| October 20, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 d33753d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 20, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorpor |
|
| September 15, 2015 |
Exhibit 99.1 Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharmas Board of Directors SANTA MONICA, Calif., September 15, 2015 (GLOBE NEWSWIRE) Kite Pharma, Inc. (Kite) (Nasdaq: KITE) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd., has been appointed to the Companys Board of Directors. Dr. Humer stated, Kite P |
|
| September 15, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 9, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commis |
|
| September 3, 2015 |
September 3, 2015 VIA FEDEX AND EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 28, 2015 |
Correspondence Charles J. Bair +1 858 550 6142 [email protected] August 28, 2015 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attention: Joel Parker Jim B. Rosenberg Christine Allen Torney RE: Kite Pharma, Inc. Form 10-K for the Fiscal Year Ended December 31, 2014 Filed March 26, 2015 Form 10-Q for the Quar |
|
| August 17, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 17, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 17, 2015 |
EX-99.1 Exhibit 99.1 Kite Pharma Provides Update on KTE-C19 Clinical Trial Kite KTE-C19 Trial on Track to Advance to Pivotal Phase 2 Kite to Host Conference Call and Webcast on August 17, 2015 at 9:00am Eastern Time SANTA MONICA, Calif., August 17, 2015 (GLOBE NEWSWIRE) ? Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today provided an update from the Company?s ongoing Phase 1/2 clinical trial of KTE-C19 |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 kite-10q20150630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 10, 2015 |
EX-10.1 2 kite-ex101196.htm EX-10.1 Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH This Agreement is based on the model |
|
| August 10, 2015 |
National Institutes of Health FIRST AMENDMENT TO L-077-2015/0 Exhibit 10.3 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended National Institutes of Health FIRST AMENDMENT TO L-077-2015/0 This is the first amendment (?First Amendment?) of the agreement by and between the National Institutes of Health (?NI |
|
| August 10, 2015 |
EX-10.2 3 kite-ex102193.htm EX-10.2 Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. Amendment #1 Cooperative Research and Development Agreement # 02716 “Cooperative Research and Development Agreement for the Development of NCI |
|
| August 10, 2015 |
Kite Pharma Reports Second Quarter 2015 Financial Results EX-99.1 2 d59684dex991.htm EX-99.1 Exhibit 99.1 Kite Pharma Reports Second Quarter 2015 Financial Results SANTA MONICA, Calif., August 10, 2015 (GLOBE NEWSWIRE) — Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported financial results for the quarter |
|
| August 10, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 10, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commissi |
|
| June 22, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 22, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 22, 2015 |
EX-99.1 Exhibit 99.1 KITE PHARMA AND BLUEBIRD BIO ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE SECOND GENERATION TCR CELL THERAPY PRODUCTS TO TREAT HPV-ASSOCIATED CANCERS Collaboration Combines bluebird bio?s Gene Editing and Lentiviral Gene Delivery Technologies and Kite?s TCR Capabilities and Exclusive Rights to a TCR Directed Against the HPV-16 E6 Oncoprotein Exclusive Worldwide Co-Development a |
|
| June 12, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 kite-10q20150331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 15, 2015 |
Kite Pharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 15, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2015 |
***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. |
|
| May 15, 2015 |
FIRST AMENDMENT TO STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NET EX-10.3 4 kite-ex1032015033129.htm EX-10.3 Exhibit 10.3 FIRST AMENDMENT TO STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NET THIS FIRST AMENDMENT TO STANDARD INDUSTRIAL /COMMERCIAL SINGLE-TENANT LEASE - NET is dated as of April 27, 2015 (this "First Amendment"), is entered into by and between 2355 UTAH INDUSTRIAL CAPITAL, LLC, a California limited liability company ("Lessor"), and KITE PHAR |
|
| May 15, 2015 |
Exhibit 10.2 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NET (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?), dated for reference purposes only as of February 17, 2015, is made by and between 2355 UTAH INDUSTRIAL CAPITAL, LLC, a California limited liability company (?Lessor |
|
| May 15, 2015 |
Kite Pharma Reports First Quarter 2015 Financial Results EX-99.1 Exhibit 99.1 Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported financial results for the quarter ended March 31, 2015. Were ve |
|
| May 15, 2015 |
Exhibit 10.4 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE ? NET (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?), dated for reference purposes only January 26, 2015, is made by and between Merritt SAB 17 LP, a California limited Partnership (?Lessor?) and Kite Pharma, Inc., a c |
|
| April 27, 2015 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 26, 2015 |
EX-10.22 2 kite-ex102220141231312.htm EX-10.22 Exhibit 10.22 ***Text Omitted and Filed Separately Execution Copy with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the Securities Act of 1933, as amended. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between AMGEN INC. and KITE PHARMA, INC. Dated as of December 31, |
|
| March 26, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 26, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 26, 2015 |
Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results EX-99.1 Exhibit 99.1 Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results SANTA MONICA, Calif., March 26, 2015 (GLOBE NEWSWIRE) Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported full-year and fourth quarter 2014 financial resu |
|
| March 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36508 KITE PHARMA, INC. |
|
| March 26, 2015 |
S-8 As filed with the Securities and Exchange Commission on March 26, 2015 Registration No. |
|
| March 26, 2015 |
THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT ? EXCLUSIVE COVER PAGE Exhibit 10.23 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT ? EXCLUSIVE COVER PAGE For NIH internal use only: License Number: L-077-2015/0 License Application Number: Serial Numbe |
|
| March 17, 2015 |
Kite Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 17, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commissio |
|
| March 2, 2015 |
Entry into a Material Definitive Agreement 8-K 1 d881132d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 24, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorp |
|
| February 19, 2015 |
EX-99.1 Exhibit 99.1 Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products SANTA MONICA, Calif., February 19, 2015 — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announce |
|
| February 19, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d875574d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 17, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorp |
|
| February 12, 2015 |
KITE / Kite Pharma, Inc. / Nussbaum Ran - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2015 |
KITE / Kite Pharma, Inc. / Bonderman David - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kite Pharma, Inc. (Name of Issuer) Ordinary Shares, $0.001 par value (Title of Class of Securities) 49803L109 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 KITE PHARMA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49803L109 (CUSIP Number) DECEMBER 31, 2014 (Date of Event That Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule |
|
| February 12, 2015 |
EX-99.1 13G CUSIP No. 49803L 10 9 Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned. Dated: February 12, 2015 Pontifax Management 2 G.P. (2007) Ltd. By: Ran Nussbaum Its: Managing Partner By: /s/ Ran Nussbaum Pontifax Ma |
|
| February 11, 2015 |
KITE / Kite Pharma, Inc. / Belldegrun Arie - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 30, 2015 |
Entry into a Material Definitive Agreement 8-K 1 d859878d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 26, 2015 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorpo |
|
| January 7, 2015 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 31, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commis |
|
| January 5, 2015 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 31, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commis |
|
| December 24, 2014 |
8-K 1 d842837d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 24, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of i |
|
| December 19, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 16, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commis |
|
| December 12, 2014 |
Table of Contents Filed Pursuant to Rule 424(b)(1) Registration Nos. 333-200615 and 333-200844 3,485,000 Shares Common Stock Kite Pharma, Inc. is offering 3,485,000 shares of its common stock. Our common stock is listed on The NASDAQ Global Select Market under the symbol “KITE.” On December 10, 2014, the last reported sale price of our common stock on The NASDAQ Global Select Market was $54.37 per |
|
| December 10, 2014 |
KITE / Kite Pharma, Inc. S-1MEF - - FORM S-1MEF As filed with the Securities and Exchange Commission on December 10, 2014 Registration No. |
|
| December 9, 2014 |
[—] Shares of Common Stock Kite Pharma, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 [—] Shares of Common Stock Kite Pharma, Inc. UNDERWRITING AGREEMENT [—], 2014 JEFFERIES LLC CREDIT SUISSE SECURITIES (USA) LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, New York 10010 Ladies and Gentlemen: Introductory. Kite Pharma, Inc., a De |
|
| December 9, 2014 |
KITE / Kite Pharma, Inc. S-1/A - - S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 9, 2014 Registration No. |
|
| November 26, 2014 |
KITE / Kite Pharma, Inc. S-1 - Registration Statement - S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on November 26, 2014 Registration No. |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 kite-10q20140930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| November 14, 2014 |
Kite Pharma Reports Third Quarter 2014 Results EX-99.1 2 d821483dex991.htm EX-99.1 Exhibit 99.1 Kite Pharma Reports Third Quarter 2014 Results SANTA MONICA, Calif., November 14, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc. (Kite) (NASDAQ: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced financial results for the third quarter |
|
| November 14, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d821483d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 14, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of i |
|
| October 14, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 7, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 14, 2014 |
EX-16.1 Exhibit 16.1 October 14, 2014 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Kite Pharma, Inc.’s statements included under Item 4.01 of its Form 8-K dated October 7, 2014, and we agree with such statements, except that we are not in a position to agree or disagree with the Company’s statements |
|
| August 15, 2014 |
EX-99.1 2 d776823dex991.htm EX-99.1 Exhibit 99.1 Kite Pharma Reports Second Quarter 2014 Results Successfully Completed Initial Public Offering, Raised Net Proceeds of $134.1 Million Kite Advancing Clinical Development Pipeline of its Proprietary eACT™-Based Product Candidates SANTA MONICA, Calif., August 14, 2014 (GLOBE NEWSWIRE) – Kite Pharma, Inc. (Kite) (NASDAQ: KITE), a clinical-stage biophar |
|
| August 15, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 14, 2014 Kite Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36508 27-1524986 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 14, 2014 |
AMended and restated BYLAWS OF KITE PHARMA, INC. ARTICLE I Offices EX-3.2 3 kite-ex3220140630615.htm EX-3.2 Exhibit 3.2 AMended and restated BYLAWS OF KITE PHARMA, INC. ARTICLE I Offices Section 1.Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36508 KITE PHARM |
|
| August 14, 2014 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KITE PHARMA, INC. EX-3.1 2 kite-ex3120140630616.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KITE PHARMA, INC. Kite Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: First:The name of this corporation is Kite Pharma, Inc. Second:The date on which the corporation’s Certificate of Incorporation was originally filed w |
|
| June 23, 2014 |
S-8 1 d746104ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 23, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KITE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 27-1524986 (State or other jurisdiction of incorporation or |
|
| June 23, 2014 |
EX-99.4 4 d746104dex994.htm EX-99.4 Exhibit 99.4 KITE PHARMA, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 6, 2014 APPROVED BY THE STOCKHOLDERS: JUNE 12, 2014 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The P |
|
| June 23, 2014 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-196081 7,500,000 Shares Common Stock Kite Pharma, Inc. is offering 7,500,000 shares of its common stock. This is our initial public offering, and no public market currently exists for our shares. The initial public offering price of our common stock is $17.00. Our common stock has been approved for listing on The NASDAQ |
|
| June 19, 2014 |
Table of Contents As filed with the Securities and Exchange Commission on June 19, 2014 Registration No. |
|
| June 17, 2014 |
EX-10.9 Exhibit 10.9 July 17, 2013 Margo Roberts, Ph.D. 511 Tulip Tree Ct Charlottesville, VA 22903 Re: Employment Letter Dear Dr. Roberts: Kite Pharma, Inc. (“Kite” or the “Company”) is pleased to offer you the position of Vice President, Research on the following terms and conditions: 1. Title; Reporting; Duties. (a) You shall serve as VP, Research for the Company and shall have such powers and |
|
| June 17, 2014 |
EX-10.17 Exhibit 10.17 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”) dated as of December 12, 2013 (the “Effective Date”), is entered into between Cabaret Biotech Ltd. (“Cabaret” |
|
| June 17, 2014 |
S-1/A As filed with the Securities and Exchange Commission on June 17, 2014 Registration No. |
|
| June 17, 2014 |
[—] Kite Pharma, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 [] Kite Pharma, Inc. UNDERWRITING AGREEMENT [], 2014 JEFFERIES LLC CREDIT SUISSE SECURITIES (USA) LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, New York 10010 Ladies and Gentlemen: Introductory. Kite Pharma, Inc., a Delaware corporation (the |
|
| June 17, 2014 |
THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT – EXCLUSIVE COVER PAGE EX-10.19 Exhibit 10.19 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT EXCLUSIVE COVER PAGE For NIH internal use only: License Number: License Application Number: A-265-2013 Seria |
|
| June 17, 2014 |
FORM 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Kite Pharma, Inc. |
|
| June 17, 2014 |
June 17, 2014 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549-3628 Attn: Jeffrey P. Riedler Bryan J. Pitko Austin Stephenson Re: Kite Pharma, Inc. Registration Statement on Form S-1 File No. 333-196081 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as am |
|
| June 17, 2014 |
Correspondence June 17, 2014 U.S. Securities and Exchange Commission VIA EDGAR Division of Corporation Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549-3628 Attn: Jeffrey P. Riedler Bryan J. Pitko Austin Stephenson Re: Kite Pharma, Inc. Registration Statement on Form S-1 File No. 333-196081 Acceleration Request Requested Date: Thursday, June 19, 2014 Requested Time: 4:00 P.M. Easte |
|
| June 11, 2014 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 11, 2014 Registration No. |
|
| June 11, 2014 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KITE PHARMA, INC. EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KITE PHARMA, INC. Kite Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of this corporation is Kite Pharma, Inc. SECOND: The date on which the corporation’s Certificate of Incorporation was originally filed with the Secretary of State of th |
|
| June 11, 2014 |
EX-10.5 Exhibit 10.5 December 17, 2012 Marc D. Better, Ph.D. 249 Sheridan Road Oakland CA 94618 Re: Employment Letter Dear Dr. Better: Kite Pharma, Inc. (“Kite” or the “Company”) is pleased to offer you the position of Vice President, Product Sciences on the following terms and conditions: 1. Title; Reporting; Duties. (a) As Vice President, Product Sciences for Kite, you will be responsible for le |
|
| June 11, 2014 |
AMENDED AND RESTATED KITE PHARMA, INC. ARTICLE I EX-3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF KITE PHARMA, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation |
|
| June 11, 2014 |
KITE PHARMA, INC. 2014 EQUITY INCENTIVE PLAN SECTION 1. EX-10.2 7 d705296dex102.htm EX-10.2 Exhibit 10.2 KITE PHARMA, INC. 2014 EQUITY INCENTIVE PLAN SECTION 1. DEFINITIONS As used herein, the following terms shall have the meanings indicated below: (a) “Administrator” shall mean the Board of Directors of the Company, or one or more Committees appointed by the Board, as the case may be. (b) “Affiliate(s)” shall mean a Parent or Subsidiary of the Compan |
